Pharma News

The research team discovered that drugs used to treat blood pressure unexpectedly increase the effect of opioids that the brain naturally produces. This can fine-tune the function of a specific brain circuit and counteract the addictive properties of opiates like fentanyl, which are used to treat pain.

New research from the University of Exeter reports the largest ever whole-genome sequencing project for the potentially fatal yeast infection Candida glabrata from hospitals across Scotland.

Lupin Limited announced the launch of Sevelamer Hydrochloride Tablets, 800 mg, having received an approval from the United States Food and Drug Administration (FDA). The product will be manufactured at Lupin's facility in Nagpur, India.

Sevelamer Hydrochloride Tablets, 800 mg is a generic equivalent of Renagel® Tablets, 800 mg of Genzyme Corporation.

Recent research reported that Ayurvedic medicine BGR-34 is effective in reducing high blood sugar levels and this reflects that the BGR-34 therapy is a more effective drug in the treatment of diabetes.

Medicago, a biopharmaceutical company headquartered in Quebec City, and GlaxoSmithKline announced that Health Canada has granted approval for COVIFENZ, COVID-19 vaccine, (plant-based virus-like particles [VLP], recombinant, adjuvanted). This vaccine is indicated for active immunization to prevent coronavirus disease 2019 (COVID‑19) caused by severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) in individuals 18 to 64 years of age.

Merck, a leading science and technology company, today announced in a European worksharing procedure (WSP) an extension to the label for metformin products in the EU - Glucophage (metformin hydrochloride [HCL] immediate release), Glucophage XR (metformin HCL extended release) and Stagid® (metformin embonate immediate release) - for use throughout pregnancy.

CTI BioPharma Corp announced the U.S. Food and Drug Administration (FDA) has approved VONJO (pacritinib) for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 10⁹/L. VONJO is a novel oral kinase inhibitor with specificity for JAK2 and IRAK1, without inhibiting JAK. The recommended dosage of VONJO is 200 mg orally twice daily.

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) has approved CARVYKTI™ (ciltacabtagene autoleucel; cilta-cel) for the treatment of adults with relapsed or refractory multiple myeloma (RRMM) after four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

Researchers find out in a recent study that omalizumab provides benefit to patients with moderate to severe allergic asthma, regardless of body mass index.